中集安瑞科(03899.HK)擬發行2026年到期16.8億港元零票息可換股債券
格隆匯11月17日丨中集安瑞科(03899.HK)發佈公吿,2021年11月16日,公司與摩根士丹利(作為經辦人)就債券發行訂立認購協議。待達成(或豁免)認購協議所載先決條件,經辦人已同意於完成日期認購及支付或促使認購人於完成日期認購及支付本金總額16.8億港元的債券。
債券可根據該等條件轉換為換股股份。根據初始換股價每股11.78港元並假設債券獲悉數轉換,債券將轉換為1.426億股換股股份,佔於該公吿日期公司已發行股本約7.0%及經發行該等換股股份擴大的已發行股本約6.6%。公司將向香港聯交所申請債券於香港聯交所上市。公司亦將向香港聯交所申請換股股份上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.